Richard L. Md Lindstrom Purchases 10,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) Director Richard L. Md Lindstrom acquired 10,000 shares of Ocular Therapeutix stock in a transaction dated Thursday, May 8th. The stock was purchased at an average cost of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director now owns 172,704 shares of the company's stock, valued at approximately $1,202,019.84. This represents a 6.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Ocular Therapeutix Stock Up 4.7%

Shares of NASDAQ:OCUL traded up $0.33 during trading hours on Monday, hitting $7.39. The company's stock had a trading volume of 1,317,808 shares, compared to its average volume of 1,419,286. Ocular Therapeutix, Inc. has a 52 week low of $4.79 and a 52 week high of $11.78. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -5.60 and a beta of 1.51. The firm's fifty day moving average price is $7.46 and its 200 day moving average price is $8.25.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The firm had revenue of $17.08 million during the quarter, compared to analysts' expectations of $16.89 million. As a group, research analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Wall Street Analysts Forecast Growth

OCUL has been the subject of several research analyst reports. William Blair assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating for the company. JMP Securities set a $19.00 target price on Ocular Therapeutix in a report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Needham & Company LLC cut their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Finally, Royal Bank of Canada assumed coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price target for the company. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. MetLife Investment Management LLC lifted its stake in shares of Ocular Therapeutix by 2.7% in the 4th quarter. MetLife Investment Management LLC now owns 92,734 shares of the biopharmaceutical company's stock valued at $792,000 after purchasing an additional 2,454 shares during the period. Teacher Retirement System of Texas lifted its stake in shares of Ocular Therapeutix by 10.0% in the 4th quarter. Teacher Retirement System of Texas now owns 27,777 shares of the biopharmaceutical company's stock valued at $237,000 after purchasing an additional 2,526 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Ocular Therapeutix by 3.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,463 shares of the biopharmaceutical company's stock valued at $755,000 after purchasing an additional 2,853 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Ocular Therapeutix in the 4th quarter valued at $28,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Ocular Therapeutix by 11.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company's stock valued at $285,000 after purchasing an additional 3,347 shares during the period. Hedge funds and other institutional investors own 59.21% of the company's stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.